Better Health for All

Xenetic Biosciences is entirely focused on developing innovative immuno-oncology technologies, including its DNase platform and XCART, to address difficult-to-treat cancers such as pancreatic carcinoma and solid tumors.

These programs aim to improve outcomes of existing treatments, indicating that the company's entire business is devoted to health improvement with exceptional health benefits. There is no evidence of products having negative health impacts. Research and development expenses increased by 105.6% to approximately $0.8 million in Q3 2025, from $0.4 million in Q3 2024. The company's revenue for Q3 2025 was approximately $1.0 million, meaning R&D expenses were 80% of revenue. The company plans to advance its DNase-based oncology technology towards Phase 1 clinical development and has entered into a Clinical Trial Services Agreement with PeriNess for potential exploratory, investigator-initiated studies in Israeli medical centers, indicating a commitment to conducting clinical studies.

Fair Money & Economic Opportunity

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on drug discovery, research, and development, not financial services.

As such, the company does not offer lending, deposit services, or other financial products to consumers. Therefore, all KPIs related to fair money and economic opportunity, such as serving underserved clients, pricing fairness, exploitative fees, financial inclusion initiatives, customer financial data accessibility, fair lending compliance, wealth-building outcomes, profit reinvestment in community finance, financial literacy programs, customer debt burden, geographic inclusion for banking services, and product simplicity for financial products, are not applicable to its core business operations.

Kind to Animals

Xenetic Biosciences, Inc. is listed on the Cruelty Free Investing list for exploiting animals.

indicating that not a single product is certified cruelty-free. The company explicitly uses preclinical animal models in its research and development, with no evidence of employing non-animal testing methods. There is no formal animal testing policy mentioned, and the company is actively engaged in preclinical development involving animal models. While specific numbers are not provided, the company's ongoing use of animal models for efficacy studies in lymphoma and metastatic melanoma suggests a significant volume of animals used annually. There is no evidence of investment in animal-free technologies or alternatives. The company collaborates with The Scripps Research Institute to advance its development program, which involves animal testing. but this collaboration does not focus on developing animal-free standards.

No War, No Weapons

The company is a biopharmaceutical firm focused on the discovery, research, and development of biologic drugs and novel therapies for various diseases, specifically advancing technology platforms for high-value cancer indications, including targeting Neutrophil Extracellular Traps (NETs) and a DNase I Oncology Platform aimed at improving cancer therapies.

This core business indicates no revenue from arms or defense contracts, no development or sale of dual-use products, and no exposure to any weapons.

Planet-Friendly Business

No specific, concrete data points related to environmental performance or planet-friendly business practices were found in the provided articles for Xenetic Biosciences, Inc.

The articles primarily focus on investor relations and financial reporting, explicitly stating the absence of information for all relevant environmental KPIs.

Respect for Cultures & Communities

The provided articles do not contain any information relevant to Xenetic Biosciences, Inc.'s performance regarding Respect for Cultures & Communities.

The articles focus on the company's business, products, financial reports, and research and development, without addressing community engagement, cultural impact, or related metrics.

Safe & Smart Tech

The company's privacy policy states that personal information is not shared.

Users can set their browser to refuse cookies, but the policy does not detail comprehensive user control options. The policy indicates that contact and demographic information is collected during registration, and IP addresses are stored as partial identifiers, suggesting limited data minimization practices. The company also mentions compliance with FDA regulations (cGMP, GCP, GLP) for manufacturing and clinical trials, as well as environmental, health, and safety laws.

Zero Waste & Sustainable Products

The company states it complies with environmental regulations regarding hazardous waste and believes its safety procedures for handling, storing, and disposing of drug candidate materials meet required state and federal environmental standards.

It notes that its compliance costs are minimal as it does not engage in manufacturing, outsourcing this process. The company does not carry a specific insurance policy to mitigate environmental risk from these materials. No other specific information regarding waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, product durability, repairability, waste audits, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education is available.